| Autor: |
Srinivasan S; Independent Journalist, 8, Seadoll, Chimbai Road, Bandra West, Mumbai 400 050, INDIA. |
| Jazyk: |
angličtina |
| Zdroj: |
Indian journal of medical ethics [Indian J Med Ethics] 2024 Jul-Sep; Vol. IX (3), pp. 234-238. |
| DOI: |
10.20529/IJME.2024.022 |
| Abstrakt: |
Nancy Olivieri is a senior haematologist and professor at the University of Toronto, Canada. In the early 1990s, she was conducting investigator-initiated research of an experimental drug, deferiprone, in children with thalassaemia, for which a pharmaceutical company, Apotex, started giving some supplemental support. In the course of her work, Dr Olivieri found that deferiprone might not be very effective and was also possibly toxic. When she signalled her intent to disclose the risks to participants, the trials were immediately shut down and she was threatened with "all legal remedies" should she disclose her concerns. This led to 18 years of attacks from the CEO of Apotex as well as fabricated charges and harassment from the University and the Hospital for Sick Children where she worked. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
